

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



06th February, 2017

To
DCS-CRD
The Secretary
Bombay Stock Exchange
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To,
National Stock Exchange of India
Limited
“Exchange Plaza”,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Sub: Unaudited Financial Results for the Quarter and nine months ended on 31st December, 2016

Scrip Code: 532637
Symbol: MANGALAM

Dear Sir,

In terms of Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter and nine months ended 31st December, 2016 along with the Limited Review Report of the said period in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on 06th February, 2017 at Mumbai.


Kindly note that the meeting of the Board of Directors commenced at 11.30 a.m and concluded at 12.55 p.m.

Further please note that the company has made necessary arrangement to publish the same in the newspapers as required under the Listing Regulations.

Kindly take the same in your records.

Thanking You,
Yours faithfully,
For Mangalam Drugs & Organics Ltd

Nikita Bavishi
Nikita Bavishi
Company Secretary.



Un-Audited Financial Results for the Quarter and Nine Month ended 31st December 2016 approved and taken on record by the Board at their meeting dated 6th February 2017

Sr. No.	Particulars	(Rs. in Lacs)					
		Unaudited			Unaudited		Audited
		Quarter ended			Nine Month ended		Year Ended
		3 months ended	3 months ended	Corresponding 3 months ended in the previous period	Year to date figures for Current period ended	Year to date figures for the previous period ended	Previous accounting year ended
31.12.16	30.09.16	31.12.15	31.12.16	31.12.15	31.03.16		
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2016							
1	Sales/Income from operation(Inclusive of excise duty)	8051.93	7643.16	8436.11	22489.55	22955.99	30314.84
2	Other Operating Income	5.91	6.75	0.00	13.98	2.72	13.89
3	Total Income from Operation	8057.84	7649.90	8436.11	22503.51	22958.71	30328.73
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	226.22	(887.30)	733.98	13.73	409.82	(7.95)
	(b) Consumption of raw materials	4570.39	6064.42	5416.92	14391.00	15723.65	20185.07
	(c) Excise duty & service tax recovered	381.93	32.70	200.68	491.90	508.87	812.66
	(d) Employee Benefits	511.15	465.01	380.72	1379.03	1024.64	1434.87
	(e) Depreciation	129.89	119.14	114.98	345.72	332.68	441.30
	(f) Other expenditure	1169.28	803.00	834.54	2805.82	2956.47	4134.02
	(g) Total	6968.86	6596.97	7661.82	19427.20	20956.13	26999.97
5	Profit(+)/Loss(-) from operations before Other Income, Finance cost and Exceptional Items(3-4)	1088.98	1052.93	774.29	3076.31	2002.58	3328.76
6	Other Income	3.65	0.71	1.51	5.18	74.43	2.02
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	1092.63	1053.64	775.80	3081.49	2077.01	3330.78
8	Finance Cost	228.00	234.91	198.12	692.88	652.15	929.18
9	Profit(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)	864.63	818.73	579.68	2388.61	1424.86	2401.60
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	864.63	818.73	579.68	2388.61	1424.86	2401.60
12	Tax Expenses(incl Deferred Tax)	245.00	235.00	200.00	675.00	375.00	798.29
13	Net Profit(+)/Loss(-) after Tax (11-12)	619.63	583.73	379.68	1713.61	1049.86	1603.31
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	619.63	583.73	379.68	1713.61	1049.86	1603.31
16	Paid up Equity Share Capital (face value Rs.10/- each)	1582.82	1582.82	1437.82	1582.82	1437.82	1437.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	3897.44
18 (i)	Earning Per Share (EPS) before extraordinary items (of Rs.10/- each) (not annualized)			2.64	10.83	7.30	11.15
	(a) Basic	3.92	3.69	2.40	10.83	6.63	10.13
	(b) Diluted	3.92	3.69	2.40	10.83	6.63	10.13
18 (ii)	Earning Per Share (EPS) after extraordinary items (of Rs.10/- each) (not annualized)			2.64	10.83	7.30	11.15
	(a) Basic	3.92	3.69	2.40	10.83	6.63	10.13
	(b) Diluted	3.92	3.69	2.40	10.83	6.63	10.13
A	INVESTOR COMPLAINTS	3 Months ended 31.12.16					
	Pending at the Beginning of the Quarter	Nil					
	Received during the Quarter	Nil					
	Disposed of during the Quarter	Nil					
	Remaining unresolved at the end of the Quarter	Nil					


Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 6th February 2017
- The above results are subject to Limited Review by Statutory Auditors
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- The CEO & CFO have certified that the Un-Audited Financial Results for the Quarter And Nine month ended 31st December 2016 do not contain any false or misleading statements or figures and do not omit any material facts which may make the statements or figures therein misleading.
- Previous year figure are regrouped wherever necessary.

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri. Govardhan M.Dhoot)
Chairman & Managing Director
DIN: 01240086

Place: Mumbai
Date: 06.02.2017





18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

Limited Review Report


Review Report to
The Board of Directors
Mangalam Drugs & Organics Limited

We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs & Organics Limited** for the period ended 31st December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature: **Mumbai**
Date: 6th February, 2017



For Milwani Associates.
For MILWANI ASSOCIATES
Chartered Accountants

(Rakesh K. Milwani) Proprietor
Membership No.: 36099
F.R.N.:106405W

RAKESH K MILWANI
Proprietor
Membership Number. 36099
Firm Reg No. 106405W